440 related articles for article (PubMed ID: 29463563)
1. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation.
Romee R; Cooley S; Berrien-Elliott MM; Westervelt P; Verneris MR; Wagner JE; Weisdorf DJ; Blazar BR; Ustun C; DeFor TE; Vivek S; Peck L; DiPersio JF; Cashen AF; Kyllo R; Musiek A; Schaffer A; Anadkat MJ; Rosman I; Miller D; Egan JO; Jeng EK; Rock A; Wong HC; Fehniger TA; Miller JS
Blood; 2018 Jun; 131(23):2515-2527. PubMed ID: 29463563
[TBL] [Abstract][Full Text] [Related]
2. Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.
Margolin K; Morishima C; Velcheti V; Miller JS; Lee SM; Silk AW; Holtan SG; Lacroix AM; Fling SP; Kaiser JC; Egan JO; Jones M; Rhode PR; Rock AD; Cheever MA; Wong HC; Ernstoff MS
Clin Cancer Res; 2018 Nov; 24(22):5552-5561. PubMed ID: 30045932
[No Abstract] [Full Text] [Related]
3. Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models.
Liu B; Jones M; Kong L; Noel T; Jeng EK; Shi S; England CG; Alter S; Miller JS; Cai W; Rhode PR; Wong HC
Cytokine; 2018 Jul; 107():105-112. PubMed ID: 29452720
[TBL] [Abstract][Full Text] [Related]
4. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
Berrien-Elliott MM; Becker-Hapak M; Cashen AF; Jacobs M; Wong P; Foster M; McClain E; Desai S; Pence P; Cooley S; Brunstein C; Gao F; Abboud CN; Uy GL; Westervelt P; Jacoby MA; Pusic I; Stockerl-Goldstein KE; Schroeder MA; DiPersio JF; Soon-Shiong P; Miller JS; Fehniger TA
Blood; 2022 Feb; 139(8):1177-1183. PubMed ID: 34797911
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma.
Xu W; Jones M; Liu B; Zhu X; Johnson CB; Edwards AC; Kong L; Jeng EK; Han K; Marcus WD; Rubinstein MP; Rhode PR; Wong HC
Cancer Res; 2013 May; 73(10):3075-86. PubMed ID: 23644531
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.
Rhode PR; Egan JO; Xu W; Hong H; Webb GM; Chen X; Liu B; Zhu X; Wen J; You L; Kong L; Edwards AC; Han K; Shi S; Alter S; Sacha JB; Jeng EK; Cai W; Wong HC
Cancer Immunol Res; 2016 Jan; 4(1):49-60. PubMed ID: 26511282
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation.
Perales MA; Goldberg JD; Yuan J; Koehne G; Lechner L; Papadopoulos EB; Young JW; Jakubowski AA; Zaidi B; Gallardo H; Liu C; Rasalan T; Wolchok JD; Croughs T; Morre M; Devlin SM; van den Brink MR
Blood; 2012 Dec; 120(24):4882-91. PubMed ID: 23012326
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of two different dose administration regimens of an IL-15 superagonist complex (ALT-803) in an orthotopic bladder cancer mouse model.
Furuya H; Chan OTM; Pagano I; Zhu C; Kim N; Peres R; Hokutan K; Alter S; Rhode P; Rosser CJ
J Transl Med; 2019 Jan; 17(1):29. PubMed ID: 30654801
[TBL] [Abstract][Full Text] [Related]
10. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
11. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
Conlon KC; Lugli E; Welles HC; Rosenberg SA; Fojo AT; Morris JC; Fleisher TA; Dubois SP; Perera LP; Stewart DM; Goldman CK; Bryant BR; Decker JM; Chen J; Worthy TA; Figg WD; Peer CJ; Sneller MC; Lane HC; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
J Clin Oncol; 2015 Jan; 33(1):74-82. PubMed ID: 25403209
[TBL] [Abstract][Full Text] [Related]
12. NK cell education after allogeneic transplantation: dissociation between recovery of cytokine-producing and cytotoxic functions.
Foley B; Cooley S; Verneris MR; Curtsinger J; Luo X; Waller EK; Weisdorf DJ; Miller JS
Blood; 2011 Sep; 118(10):2784-92. PubMed ID: 21757615
[TBL] [Abstract][Full Text] [Related]
13. The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques.
Webb GM; Molden J; Busman-Sahay K; Abdulhaqq S; Wu HL; Weber WC; Bateman KB; Reed JS; Northrup M; Maier N; Tanaka S; Gao L; Davey B; Carpenter BL; Axthelm MK; Stanton JJ; Smedley J; Greene JM; Safrit JT; Estes JD; Skinner PJ; Sacha JB
PLoS Pathog; 2020 Mar; 16(3):e1008339. PubMed ID: 32163523
[TBL] [Abstract][Full Text] [Related]
14. New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity.
Bailey CP; Budak-Alpdogan T; Sauter CT; Panis MM; Buyukgoz C; Jeng EK; Wong HC; Flomenberg N; Alpdogan O
Oncotarget; 2017 Jul; 8(27):44366-44378. PubMed ID: 28574833
[TBL] [Abstract][Full Text] [Related]
15. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation.
Laport GG; Sheehan K; Baker J; Armstrong R; Wong RM; Lowsky R; Johnston LJ; Shizuru JA; Miklos D; Arai S; Benjamin JE; Weng WK; Negrin RS
Biol Blood Marrow Transplant; 2011 Nov; 17(11):1679-87. PubMed ID: 21664472
[TBL] [Abstract][Full Text] [Related]
17. IL-15 Superagonist Expands mCD8+ T, NK and NKT Cells after Burn Injury but Fails to Improve Outcome during Burn Wound Infection.
Patil NK; Luan L; Bohannon JK; Guo Y; Hernandez A; Fensterheim B; Sherwood ER
PLoS One; 2016; 11(2):e0148452. PubMed ID: 26859674
[TBL] [Abstract][Full Text] [Related]
18. First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia.
Cooley S; He F; Bachanova V; Vercellotti GM; DeFor TE; Curtsinger JM; Robertson P; Grzywacz B; Conlon KC; Waldmann TA; McKenna DH; Blazar BR; Weisdorf DJ; Miller JS
Blood Adv; 2019 Jul; 3(13):1970-1980. PubMed ID: 31266741
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer.
Geller MA; Cooley S; Judson PL; Ghebre R; Carson LF; Argenta PA; Jonson AL; Panoskaltsis-Mortari A; Curtsinger J; McKenna D; Dusenbery K; Bliss R; Downs LS; Miller JS
Cytotherapy; 2011 Jan; 13(1):98-107. PubMed ID: 20849361
[TBL] [Abstract][Full Text] [Related]
20. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
Basher F; Jeng EK; Wong H; Wu J
Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]